Every material Form 8-K Cytokinetics has filed with the SEC since August 15, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cytokinetics reported third quarter 2026 results, with total revenue of $47.6 million, up from $1.9 million a year earlier, driven by $44.5 million in MYQORZO net product revenue. The net loss narrowed to $190.1 million, or $1.37 per share, from $306.2 million, or $2.55 per share, a year earlier, and the company reaffirmed its full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million.
Total Q3 2026 revenue was $47.6 million, including $44.5 million of MYQORZO net product revenue and $3.1 million of collaboration revenue.
Net loss for Q3 2026 was $190.1 million, or $(1.37) per share, versus $306.2 million, or $(2.55) per share, in Q3 2025.
Cash, cash equivalents and investments were approximately $1.6 billion at September 30, 2026, compared with $1.7 billion at June 30, 2026.
Full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million was reaffirmed.
Cytokinetics reported second quarter 2026 total revenue of $28.6 million, down from $66.8 million a year earlier, when the company recorded $64.4 million in license and milestone revenue. The net loss widened to $198.8 million, or $(1.50) per share, from $134.4 million, or $(1.12) per share. The company also raised its full year 2026 GAAP combined R&D and SG&A expense guidance, which it attributed to commercial readiness investments ahead of a potential 2027 nHCM launch of MYQORZO.
Total revenue was $28.6 million in Q2 2026 versus $66.8 million in Q2 2025; Q2 2026 had no license and milestone revenue.
MYQORZO net product revenue was $25.3 million, including $23.0 million from the U.S. and $2.3 million from Europe.
Net loss was $198.8 million, or $(1.50) per share, compared with $134.4 million, or $(1.12) per share, a year earlier.
2026 GAAP combined R&D and SG&A expense guidance rose to $860 million to $890 million from $830 million to $870 million.
Cytokinetics reported first quarter 2026 results, with total revenues of $19.4 million versus $1.6 million a year earlier, including $4.8 million of MYQORZO net product revenue from its initial partial quarter of U.S. sales. The net loss widened to $206.0 million, or $(1.67) per share, from $161.4 million, or $(1.36) per share, as selling, general and administrative expenses rose to $104.9 million, and the company maintained its full year 2026 guidance.
MYQORZO net product revenue was $4.8 million, covering about 9 weeks of U.S. sales in the first quarter.
Revenue included an $11.9 million milestone tied to the first U.S. sale of MYQORZO under the Bayer license agreement.
SG&A expenses were $104.9 million versus $57.4 million a year earlier, mainly due to external costs of the MYQORZO commercial launch.
Cash, cash equivalents and investments were approximately $1.1 billion at March 31, 2026, down from $1.2 billion at December 31, 2025; full year 2026 combined GAAP R&D and SG&A guidance of $830 million to $870 million was maintained.
Cytokinetics reported fourth quarter and full year 2025 results and gave 2026 guidance, while its MYQORZO heart drug launches in the U.S. Revenue rose from a year earlier, but the net loss widened sharply as the company built out its commercial operations. The company's 2026 GAAP combined R&D and SG&A expense guidance of $830 million to $870 million signals continued heavy spending.
Q4 2025 total revenues were $17.8 million, up from $16.9 million in Q4 2024; full year 2025 revenues were $88.0 million, up from $18.5 million.
Q4 2025 net loss was $183.0 million, or $(1.50) per share, versus a $150.0 million loss, or $(1.26) per share, a year earlier; full year net loss was $785.0 million, or $(6.54) per share, versus $589.5 million, or $(5.26) per share, in 2024
Cash, cash equivalents and investments were approximately $1.22 billion at December 31, 2025, including $100 million from a Royalty Pharma loan tranche.
2026 GAAP combined R&D and SG&A expense guidance is $830 million to $870 million.
Cytokinetics said it hired Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025, under an offer letter dated November 13, 2025. He most recently served as Executive Vice President and General Counsel of Exelixis, Inc. The filing sets out a $660,000 base salary, a $400,000 signing bonus, and a $5.8 million initial restricted stock unit award, which gives the role a defined pay structure for shareholders to track.
Start date: November 14, 2025; base salary initially $660,000
Target annual bonus 50% of base salary, with 75% tied to corporate goals
Signing bonus of $400,000, partly subject to repayment if he leaves within one year
Initial RSU award with a grant date value of $5,800,000, vesting 40%, 40% and 20% over three years
Cytokinetics reported third quarter 2025 results on November 5, 2025, with revenue of $1.9 million, up from $0.5 million a year earlier. The net loss widened to $306.2 million, or $(2.55) per share, from $160.5 million, or $(1.36) per share, including a $121.2 million debt conversion expense tied to the exchange of $399.5 million of 2027 Notes. The company narrowed its full-year 2025 GAAP operating expense guidance to $680 million to $700 million from $670 million to $710 million, and said it is preparing for the December 26, 2025 FDA action date for aficamten.
Q3 2025 total revenues were $1.9 million, compared with $0.5 million in Q3 2024.
Q3 2025 net loss was $306.2 million, or $(2.55) per share, versus $160.5 million, or $(1.36) per share, a year earlier.
Full-year 2025 GAAP operating expense guidance is $680 million to $700 million, versus a prior range of $670 million to $710 million.
Cash, cash equivalents and investments were approximately $1.25 billion as of September 30, 2025.
On September 19, 2025, Cytokinetics issued $750.0 million of 1.75% convertible senior notes due October 1, 2031, including the full $100.0 million option granted to the initial purchasers. The company estimates net proceeds of about $729.4 million, and expects to use about $402.5 million in cash, plus 2,168,806 new common shares, to exchange about $399.5 million of its 3.50% notes due 2027, which extends that debt to 2031. Conversion at the initial price of about $68.42 per share could dilute existing shareholders if the notes are converted into shares.
$750.0 million principal issued September 19, 2025, including the full $100.0 million option
About $399.5 million of 3.50% 2027 notes to be exchanged for 2,168,806 shares plus about $402.5 million in cash
Initial conversion price of about $68.42, a 37.5% premium to the $49.76 closing price on September 16, 2025
Company may not redeem the notes before October 6, 2028
Cytokinetics appointed James M. Daly to fill a vacant Board seat effective August 19, 2025, as a Class III director with a term expiring at the 2028 annual meeting. The Board determined he is independent, and he joins the Compliance Committee. The filing describes a routine board addition with standard director compensation and no reported related-party transactions.
Daly appointed to a vacant Board seat effective August 19, 2025; term expires at the 2028 annual meeting
Initial grant: option to purchase 27,450 shares with a grant date fair value of $700,000, vesting monthly over three years
Annual compensation includes a $50,000 Board retainer, a $7,500 Compliance Committee retainer, and equity grants with an aggregate fair value of $440,000
Cytokinetics reported second quarter 2025 revenue of $66.8 million, up from $0.2 million a year earlier, largely from a $52.4 million Japan license recognition with Bayer. The net loss narrowed to $134.4 million, or $(1.12) per share, from $143.3 million, or $(1.31) per share, and the company maintained its full year 2025 GAAP operating expense guidance of $670 million to $710 million.
Total Q2 2025 revenue was $66.8 million, including $52.4 million from the Bayer Japan license and $11.7 million from clinical milestones.
Net loss was $134.4 million, or $(1.12) per share, versus $143.3 million, or $(1.31) per share, in Q2 2024.
2025 GAAP operating expense guidance of $670 million to $710 million was maintained.
Cash, cash equivalents and investments were approximately $1.0 billion as of June 30, 2025, down $52.6 million in the quarter.
Cytokinetics reported first quarter 2025 results, with revenue of $1.6 million, up from $0.8 million a year earlier, but a net loss of $161.4 million, or $(1.36) per share, versus a $135.6 million loss, or $(1.33) per share, in the first quarter of 2024. The FDA extended the review target date for aficamten in obstructive HCM to December 26, 2025, and the company maintained its full-year 2025 GAAP operating expense guidance of $670 million to $710 million.
Q1 2025 revenue was $1.6 million, compared with $0.8 million in Q1 2024.
Q1 2025 net loss was $161.4 million, or $(1.36) per share, compared with $135.6 million, or $(1.33) per share, a year earlier.
R&D expenses rose to $99.8 million from $81.6 million, and G&A expenses rose to $57.4 million from $45.5 million.
The FDA extended the aficamten PDUFA date to December 26, 2025; cash, cash equivalents and investments were about $1.1 billion at March 31, 2025.
Cytokinetics reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue rose sharply, but the net loss grew in dollar terms, and the company guided to 2025 GAAP operating expense of $670 million to $710 million as it prepares for a possible aficamten launch.
Q4 2024 total revenues were $16.9 million, up from $1.7 million in Q4 2023, benefiting from a $15.0 million upfront payment from Corxel.
Q4 2024 net loss was $150.0 million, or $(1.26) per share, versus $136.9 million, or $(1.38) per share, in Q4 2023.
Full-year 2024 net loss was $589.5 million, or $(5.26) per share, versus $526.2 million, or $(5.45) per share, in 2023.
2025 GAAP operating expense guidance is $670 million to $710 million; cash, cash equivalents and investments were approximately $1.2 billion at December 31, 2024.
Cytokinetics' Board appointed Robert E. Landry as a director on February 10, 2025, filling a vacant seat as a Class II member with a term expiring at the 2027 annual meeting, and also named him to the Audit Committee. The Board determined he is independent, and the filing describes his director pay, including a $440,000 annual equity grant and a one-time option grant with a $700,000 fair value.
Robert E. Landry appointed to fill a vacant Board seat effective February 10, 2025; term expires at the 2027 annual meeting.
Named to the Board's Audit Committee; annual retainer of $12,500 for that role plus a $50,000 Board retainer.
Annual equity grant with a $440,000 grant date fair value; one-time Initial Grant option with a $700,000 grant date fair value vesting over three years.
Cytokinetics said its Chief Accounting Officer, Robert Wong, will leave the company effective December 31, 2024, and that there is no disagreement with him on financial condition or reporting. Chief Financial Officer Sung Lee, who joined in May 2024, will also take on the role of principal accounting officer when Wong departs, so the change is administrative and does not add a new executive.
Robert Wong, Chief Accounting Officer and principal accounting officer, departs effective December 31, 2024
Sung Lee, CFO since May 2024, will additionally serve as principal accounting officer upon Wong's departure
Filing states no disagreement between Wong and the company on financial condition or financial reporting
Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.
Upfront payment of €50 million from Bayer
Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K
Cytokinetics said director Santo J. Costa resigned from its Board of Directors with immediate effect, notice given November 1, 2024. The company said the resignation was for personal reasons and not due to any disagreement with the company, and the board was reduced from nine to eight directors.
Santo J. Costa resigned from the Board of Directors effective immediately; notice was given November 1, 2024.
The company said the resignation was for personal reasons, not a disagreement on operations, policies, or practices.
Board size was reduced from nine to eight directors.
Cytokinetics hired Brett Pletcher as Executive Vice President, Chief Legal Officer, effective August 19, 2024, under an offer letter dated August 13, 2024. The filing sets his $560,000 base salary and a 45% target bonus, along with sign-on and initial equity awards, which are routine terms for a senior executive hire.
Start date is August 19, 2024; base salary is $560,000
Target bonus is 45% of base salary; signing bonus is $100,000
Initial equity awards include RSUs and options each valued at $1,891,620, and PSUs valued at $833,520 at target
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cytokinetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →